Laprafylline

This classification denotes a bronchodilator with the molecular formula C29H36N6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F427P36M7J, chemically known as 1-methyl-3-isobutyl-8-(2-ethyl(1-(4-diphenylmethylpiperazinyl)))-3,7-dihydro-(1h)-purine 2,6-dione but generally known as laprafylline, which bears US NIH Compound Identifier 65821. European Medicines Agency schedules Laprafylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08405MIG. The term LAPRAFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). LAPRAFYLLINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule laprafylline under HS 29395900 and SITC 54145. As of Q4 2014, LAPRAFYLLINE remains the US FDA Preferred Term for this commodity. Laprafylline bears US NLM identifiers UMLS ID C0073782 and NCI Concept Code C96198. SMILES: O=C1N(C(=O)N(C2NC([NH]C12)CCN1CCN(CC1)C(C1CCCCC1)C1CCCCC1)CC(C)C)C.